A New Era in Prostate Cancer Treatment
A groundbreaking therapy is set to transform the lives of thousands of men diagnosed with prostate cancer in England. The new treatment, known as stereotactic ablative radiotherapy (SABR), offers a more efficient and less invasive approach to managing the disease. By significantly reducing the number of hospital visits required for treatment, this precision radiotherapy method provides patients with a more convenient and effective option.
How SABR Works
SABR delivers higher doses of radiation to the tumour from multiple angles, allowing doctors to target the cancer with greater accuracy. This technique not only minimizes damage to surrounding healthy tissue but also reduces the risk of the cancer growing or spreading. Unlike traditional radiotherapy, which typically requires at least 20 sessions, SABR can be completed in just five doses over a two-week period. This reduction in treatment sessions helps ease the burden on both patients and the NHS by freeing up capacity and reducing waiting times.
Widespread Availability
NHS England has announced that all 48 radiotherapy centres across the country will begin offering SABR to men with early-stage prostate cancer within the next three months. Some centres are expected to start using the treatment as early as next week, following successful UK-led clinical trials that demonstrated its effectiveness. The therapy is particularly beneficial for men with low or intermediate-risk prostate cancer, who may be eligible for this advanced form of treatment.
Approximately 17,500 men are diagnosed with this type of prostate cancer each year in England, and around 3,500 of them could take advantage of SABR, according to NHS England’s modelling. However, many others opt for active surveillance, where the cancer is monitored closely until it shows signs of becoming more aggressive.
Expert Endorsement
Sir Jim Mackey, chief executive of NHS England, praised the new treatment, stating that it would “transform treatment for thousands of men with prostate cancer.” He emphasized that the therapy would help reduce side effects and the “to-and-fro” burden of frequent hospital visits, which can be physically and emotionally draining for patients and their families.
Professor Peter Johnson, NHS national clinical director for cancer, highlighted the benefits of SABR in targeting cancer precisely while minimizing harm to healthy cells. He noted that the treatment can be delivered in 15 fewer sessions than conventional radiotherapy, helping men return to their daily lives more quickly.
Impact on Prostate Cancer Care
Prostate cancer is the most common cancer among men in the UK, with over 55,000 diagnoses each year and approximately 12,300 deaths attributed to the disease. The introduction of SABR represents a significant step forward in improving outcomes for patients and reducing the strain on healthcare services.
The Daily Mail has long advocated for better diagnosis and treatment options for prostate cancer, aiming to reduce preventable deaths. NHS England estimates that the rollout of SABR could free up around 50,000 appointments annually, helping to address long waiting lists.
Amy Rylance, director of health services at Prostate Cancer UK, welcomed the development, noting that the shift from 20 hospital visits to just five would greatly reduce the burden on patients and their families. She also highlighted the organization’s role in supporting research into the safety and effectiveness of SABR, and its ongoing efforts to explore whether the treatment could benefit even more men, including those with advanced disease.
David James, director of patient projects and influencing at Prostate Cancer Research, echoed these sentiments, emphasizing the importance of making this treatment widely available. He urged the NHS to roll out SABR as quickly as possible so that all eligible men can access the latest advances in care.
Dr Nicky Thorp, vice-president for clinical oncology at the Royal College of Radiologists, expressed enthusiasm about the expansion of SABR. She explained that the treatment is designed to deliver high-dose radiation to tumours while preserving healthy tissue, resulting in fewer side effects and improved quality of life for patients.
Future Prospects
As part of the National Cancer Plan, the government has committed to improving access to cutting-edge cancer treatments across England. With the rollout of SABR, the NHS is taking a major step toward achieving this goal. Experts hope to see this world-class form of radiotherapy become more widely available to patients who could benefit from it.
Sir Jim Mackey will discuss the role of technology and local innovation in improving patient experiences during a speech at the NHS ConfedExpo conference in Manchester today. His address will highlight how advancements in treatment can help reduce waiting times and enhance the overall care journey for patients.
No comments:
Post a Comment